Novartis's Patupilone Fails In Phase III TrialsJune 2010 | Company Brief
To read the full article, please choose one of the following options:
News: Swiss pharmaceutical company Novartis has announced that its experimental drug EPO906 (patupilone) failed to meet its primary endpoint in a phase III trial of patients with advanced ovarian cancer, refractory or resistant to platinum-based therapy. The study was conducted in approximately 168 locations in 22 countries on 829 patients suffering from epithelial ovarian, primary fallopian or primary peritoneal cancer. The drug was compared with Doxil/Caelyx (pegylated liposomal doxorubicin) in the trial.